AstraZeneca sees stock market value slump by more than £20bn after drug setback - The FTSE 100 firm found the Wainua drug ...

Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.

AstraZeneca loses £20 billion in value after disappointing trial results for a key heart disease drug. Find out more.

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...

Heavy falls in AstraZeneca saw London’s FTSE 100 underperform European peers, while investors continue to weigh up ...

Astra's shares tumbled 10.5% after it said its Wainua drug - which it is developing with Ionis - failed to reduce deaths ...

Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation July 6, 2026 9:30 AM ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. AstraZeneca is in focus after analysts trimmed their fair value estimate for the ...

AstraZeneca shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its ...